These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20361265)

  • 21. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted agents: how to select the winners in preclinical and early clinical studies?
    Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
    Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
    Seymour L
    Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
    Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
    Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving paradigms for new agent development in pediatric oncology.
    Flynn A; Fox E
    Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Envisioning the future of early anticancer drug development.
    Yap TA; Sandhu SK; Workman P; de Bono JS
    Nat Rev Cancer; 2010 Jul; 10(7):514-23. PubMed ID: 20535131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol.
    Djebbari F; Stoner N; Lavender V
    Syst Rev; 2017 Dec; 6(1):244. PubMed ID: 29208047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trials of targeted anticancer drugs: a need to refocus.
    Borden EC; Dowlati A
    Nat Rev Drug Discov; 2012 Dec; 11(12):889-90. PubMed ID: 23197020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know.
    Ali A; Shah AA; Jeang LJ; Fallgatter KS; George TJ; DeRemer DL
    Cancer Treat Rev; 2022 Apr; 105():102376. PubMed ID: 35303547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
    Roda D; Jimenez B; Banerji U
    Clin Cancer Res; 2016 May; 22(9):2127-32. PubMed ID: 26581244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
    Maeda H; Kurokawa T
    Invest New Drugs; 2014 Aug; 32(4):661-9. PubMed ID: 24615632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New cast for a new era: preclinical cancer drug development revisited.
    Herter-Sprie GS; Kung AL; Wong KK
    J Clin Invest; 2013 Sep; 123(9):3639-45. PubMed ID: 23999436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.